Chinese drug delivery company "Xin Maide" has secured nearly 300 million yuan in Series B funding, led by Suzhou Industrial Park Yuanhe Yuandian Venture Capital. The company plans to use the funds to advance its drug delivery technology platform, focusing on pulmonary and nasal administration. This funding will also bolster their capabilities in original research, precision engineering, industrialization, and global partnerships. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
IMPACT Niche tooling improvement; minimal industry-wide impact.
RANK_REASON Significant funding round for a company in the drug delivery sector.